Bristol-Myers Squibb Company (BMY)
BMY or VRTX: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Bristol Myers Squibb (BMY) and Vertex Pharmaceuticals (VRTX). But which of these two stocks offers value investors a better bang for their buck right now?
A Market Crash Could Ruin Baby Boomers: 5 Safe High-Yield Dividend Stocks and Advice
24/7 Wall St. Insights The 2025 Social Security COLA will be only 2.5%.
Bristol Myers Squibb (BMY) Stock Falls Amid Market Uptick: What Investors Need to Know
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $52.20, denoting a -0.38% change from the preceding trading day.
BMY Buoyed by Recent Regulatory Updates: How to Play the Stock?
While the recent spate of positive regulatory updates boosts Bristol Myers, we will advise a wait-and-watch strategy.
Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Bristol Myers Squibb: A High-Yield Bargain With Growth On The Horizon
Frequent trading can erode gains due to transaction costs and taxes; a buy-and-hold strategy is often more effective for retail investors. Bristol Myers Squibb offers a strong dividend yield, below-average valuation, and solid growth prospects, making it a compelling buy. BMY's robust pipeline, including advancements in neurodegenerative therapies, and strong balance sheet support future growth and income potential.
Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors
The latest trading day saw Bristol Myers Squibb (BMY) settling at $54.20, representing a +0.82% change from its previous close.
2 Passive-Income Stocks to Load Up On in October
These two dividend powerhouses are ideal choices for passive-income investors.
Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug
Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for the cancer drug Breyanzi and two other drugs developed by Celgene.
3 Surprisingly Underrated Stocks to Buy Right Now
Bristol Myers Squibb is trading at a significant discount. Moderna has a lot of irons in the fire.
Bristol-Myers Squibb Likely To Revalue Higher Following New Drug Approval
Bristol-Myers Squibb's stock is poised to rise due to the FDA approval of Cobenfy, a novel antipsychotic for schizophrenia, and improved technicals. The company's $14 billion acquisition of Karuna Therapeutics and subsequent drug approval validates the investment and supports a higher stock price. BMY's strong oncology portfolio, including Opdivo and Revlimid, and recent acquisitions bolster its fundamentals, targeting a price range of $59.50 to $61.60.
Bristol Myers Squibb stock rises following FDA approval of its schizophrenia drug
CNBC's Angelica Peebles joins 'Fast Money' to report on Bristol Myers Squibb's stock rise following FDA approval of Cobenfy for treating schizophrenia in adults.
